COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES

被引：2
|
作者：
Ortendahl, J. D. [1 ]
Bentley, T. G. [1 ]
Anene, A. M. [1 ]
Purdum, A. G. [2 ]
Bolinder, B. [2 ]
机构：
[1] Partnership Hlth Analyt Res LLC, Beverly Hills, CA USA
[2] Bristol Myers Squibb Co, Plainsboro Township, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.500
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN105
引用
收藏
页码：A86 / A86
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
  • [2] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
  • [3] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN
    Moreno, V
    Martinez-Amores, B.
    Barriuso, J.
    Mezquita, L.
    Ibanez de Caceres, I.
    Ayuso, A.
    Pena, J. M.
    Perona, R.
    Grande, E.
    Belda-Iniesta, C.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A421 - A422
  • [4] Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain
    Moreno, Victor
    Martinez-Amores, Brezo
    Barriuso, Jorge
    Mezquita, Laura
    Ibanez de Caceres, Inmaculada
    Ayuso Sacido, Angel
    Maria Pena, Jose
    Perona, Rosario
    Belda-Iniesta, Cristobal
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Rodriguez, R.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A433 - A434
  • [6] Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 194 - 198
  • [7] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [8] Cetuximab for the first-line treatment of metastatic colorectal cancer
    Meads, C.
    Round, J.
    Tubeuf, S.
    Moore, D.
    Pennant, M.
    Baylis, S.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 1 - 8
  • [9] Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
    Aguiar-Ibanez, Raquel
    Hardern, Chloe
    van Hees, Frank
    Lee, Dawn
    Patel, Anubhav
    Chhabra, Nitika
    Baluni, Gargi
    Amonkar, Mayur
    Lai, Yizhen
    Xu, Ruifeng
    Massaad, Rachid
    Fogelman, David
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 469 - 480
  • [10] Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer
    Giuliani, Jacopo
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1674 - 1676
12345